<DOC>
	<DOCNO>NCT01756079</DOCNO>
	<brief_summary>This study do find addition boceprevir standard care ( SOC ) treatment peginterferon alfa-2b ( PegIFN-2b ) + ribavirin ( RBV ) effective participant chronic hepatitis C ( CHC ) genotype 1 cirrhosis successfully treat previous SOC . All participant receive treatment SOC alone 4 week boceprevir add treatment regimen 44 additional week combine treatment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Boceprevir Added Standard Care Therapy Previously Treated Participants With Chronic Hepatitis C Genotype 1 Cirrhosis ( MK-3034-105 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Inclusion criterion : Weight 40 kg 125 kg Documented CHC genotype 1 infection Previous course treatment SOC ( PegIFN2a PegIFN2b + RBV ) document nonresponse Documented diagnosis cirrhosis No evidence hepatocellular carcinoma ( HCC ) ultrasound Participant partner participant must agree use 2 effective contraceptive specify least 2 week prior Day 1 treatment continue least 6 month last dose study drug ( 7 month male participant ) Exclusion criterion : Coinfection human immunodeficiency virus ( HIV ) hepatitis B virus Use investigational drug within 30 day prior study enrollment Participation clinical trial within 30 day study enrollment intention participate another clinical trial study Evidence present previous decompensated liver disease include , limited , history presence clinical ascites hepatic encephalopathy . Only participants large ( F3 ) esophageal varix , determine esophagogastroduodenoscopy ( EGD ) perform within past 12 month accord international guideline exclude . Clinically significant ocular examination finding Preexisting significant psychiatric condition ( ) Clinical diagnosis active recent substance abuse Evidence active suspect malignancy , history malignancy , within last 3 year ( except adequately treat carcinoma situ basal cell carcinoma skin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>